Attovia Therapeutics

Recent news

• Morgan Stanley Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $39
  Market Newswire · 2026/9/3
• LifeSci Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
  Market Newswire · 2026/8/31
• Rating change
  RBC Capital Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $45
  Market Newswire · 2026/8/31
• Rating change
  Morgan Stanley Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $39
  Market Newswire · 2026/8/31
• LifeSci Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/9/5
• Rating change
  Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO)
  TipRanks · 2026/9/3
• Citi Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/9/4
• RBC Capital Maintains Attovia Therapeutics(ATTO.US) With Buy Rating, Maintains Target Price $45
  Market Newswire · 2026/9/3
• Rating change
  Citi Initiates Attovia Therapeutics(ATTO.US) With Buy Rating, Announces Target Price $30
  Market Newswire · 2026/8/31
• Rating change
  Analysts Offer Insights on NA Companies: Attovia Therapeutics, Inc. (ATTO) and Navan, Inc. Class A (NAVN)
  TipRanks · 2026/9/4

Headlines are aggregated automatically and are not independently verified or edited by our team.